Could a single cell treatment free liver transplant patients from daily anti-rejection pills?

NCT ID NCT05234190

First seen Mar 04, 2026 · Last updated May 14, 2026 · Updated 15 times

Summary

This study tests a new treatment called QEL-001, made from a patient's own cells, to help their body accept a donated liver without needing lifelong anti-rejection drugs. About 33 adults who received a liver transplant 1 to 5 years ago will receive the therapy and then try to stop their current immunosuppression. The goal is to see if the treatment is safe and can prevent organ rejection after stopping standard medications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cambridge University Hospitals NHS Foundation Trust

    Cambridge, CB2 0QQ, United Kingdom

  • G. Gergorio Maranon

    Madrid, Spain

  • H. Clinic Barcelona

    Barcelona, Spain

  • H. Saint Luc

    Brussels, Belgium

  • Hopital Erasme

    Brussels, Belgium

  • Hospital Reina Sofia

    Córdoba, Spain

  • King's College Hospital NHS Foundation Trust

    London, SE5 9RS, United Kingdom

  • Queen Elizabeth Hospital

    Birmingham, United Kingdom

  • Royal Free London NHS Foundation Trust

    London, NW3 2QG, United Kingdom

  • UZ Leuven

    Leuven, 3000, Belgium

Conditions

Explore the condition pages connected to this study.